Navigation Links
Human Genome Sciences to Sponsor Conference Call to Discuss First Quarter 2009 Financial Results

ROCKVILLE, Md., April 22 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it will sponsor a conference call to discuss its financial results for the quarter ended March 31, 2009. These results are expected to be disclosed on Wednesday, April 29, 2009, after the capital markets close.

(Logo: )

The conference call will be hosted by senior management and will be held on Wednesday, April 29, 2009 at 5:00 pm Eastern time.

Investors may listen to the call by dialing 877-591-4959 or 719-325-4901, passcode 2810740, five to 10 minutes before the start of the call. A replay of the conference call will be available within a few hours after the call ends. Investors may listen to the replay by 888-203-1112 or 719-457-0820, confirmation code 2810740.

This conference call also will be webcast and may be accessed at Investors interested in listening to the live webcast should log on before the conference call begins in order to download any software required. The archive of the conference call will remain available for several days.

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc.


This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, while the Company has begun shipment of ABthrax to the U.S. Strategic National Stockpile, the Company will continue to face risks related to acceptance of future shipments and FDA's approval of the Company's Biologics License Application for ABthrax, if and when it is submitted. If the Company is unable to meet requirements associated with the ABthrax contract, future revenues from the sale of ABthrax to the U.S. Government will not occur. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
2. ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Mesenchymal Cells
3. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Citi Conference
4. Human Genome Sciences and Morphotek(R), Inc. Announce Collaboration to Discover, Develop and Commercialize Antibodies for Oncology and Immunology
5. ArunA Biomedical, Inc. Announces Alliance with Neuromics for Distribution of Normal Human Neural Cells
6. Proteomics Study Reveals That Genes Involved in Invertebrate Longevity Have Surprising Parallels in Humans.
7. IEEE Celebrates Its 125th Anniversary Presenting Emerging, World Changing Technologies During Its Embracing Human Technology Interactions Media Event
8. Human Genome Sciences to Sponsor Conference Call
9. Human Genome Sciences to Sponsor Conference Call to Discuss Full Year 2008 Financial Results
10. Human Genome Sciences to Receive $9 Million Milestone Payment Related to GlaxoSmithKline Initiation of Phase 3 Clinical Trial of Syncria(R) in Type 2 Diabetes
11. China Biologic Products High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan
Post Your Comments:
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... RALEIGH, N.C. , Nov. 24, 2015  Clintrax Global, Inc., ... Raleigh, North Carolina , today announced that the company has ... earnings represented a 391% quarter on quarter growth posted for Q3 ... Kingdom and Mexico , with the ... place in December 2015. --> United Kingdom ...
(Date:11/24/2015)... New York , November 24, 2015 ... to a recent market research report released by Transparency ... projected to expand at a CAGR of 17.5% during ... "Non-invasive Prenatal Testing Market - Global Industry Analysis, Size, ... estimates the global non-invasive prenatal testing market to reach ...
Breaking Biology Technology:
(Date:11/9/2015)... SAN JOSE, Calif. , Nov. 9, 2015 /PRNewswire/ ... of human interface solutions, today announced broader entry into ... of vehicle-specific solutions that match the pace of consumer ... drivers, and biometric sensors are ideal for the automotive ... the vehicle. Europe , ...
(Date:10/29/2015)... 29, 2015   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that it ... (MHTA) as one of only three finalists for a ... Small and Growing" category. The Tekne Awards honor ... superior technology innovation and leadership. iMedNet™ ...
(Date:10/29/2015)... ANN ARBOR, Mich. , Oct. 29, 2015 ... with Eurofins Genomics for U.S. distribution of its ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq ... DNA to enable the preparation of NGS libraries ... in plasma for diagnostic and prognostic applications in ...
Breaking Biology News(10 mins):